82 News reports on Senator Hatch pressure over Colombia compulsory license on Novartis drug

(More on Colombia here: /colombia)

• 17 June 2016. Novartis Rejects Claims It Is Pushing Out Generic Competition Of Cancer Drug. Inside U.S. Trade.
• 16 June 2016. Brett Fortnam. Colombia To Reduce Price Of Swiss Cancer Drug In Lieu Of Compulsory License. Inside U.S. Trade.
• 14 June 2016. Ed Silverman. Novartis, Colombia face off over cancer drug cost. Pharmalot/Stat News.
• 14 June 2016. Daniel R. Hoffman. Hillary & Trump: Who’s better/worse for affordable drug prices? The Philadelphia Inquirer.
• 14 June 2016. Mackenzie Bean. Novartis clashes with Colombia over high drug costs. Becker’s Hospital Review.
• 13 June 2016. Eric Sagonowsky. Unswayed by pushback, Colombia moves to ‘unilaterally’ set price for Novartis’ Gleevec. FiercePharma.
• 13 June 2016. Brett Norman. INDUSTRY PUSHES BACK ON COLOMBIA MOVE TO LOWER DRUG PRICE. POLITICO Prescription Pulse.
• 10 June 2016. Adam Behsudi. Colombia makes move on drug price. POLITICO Morning Trade.
• 9 June 2016. Emisión Central del Noticiero CM&.
• 9 June 2016. Colombia: Gobierno detiene negociación con Novartis por Imatinib. Cluster Salud.
• 9 June 2016. De manera unilateral Min. Salud bajará precios de medicamento contra el cáncer. Publimetro.co
• 9 June 2016. Gobierno rompe negociación con Novartis y fijará precio del Imatinib. El Colombiano.
• 9 June 2016. Joshua Goodman. Colombia to force Novartis to lower prices of cancer drug. Associated Press.
• 9 June 2016. Julia Symmes Cobb and Luis Jaime Acosta. Colombia to set new price for Novartis cancer drug: minister. Reuters.
• 9 June 2016. Ed Silverman. Colombia plans to unilaterally lower the cost of a Novartis cancer drug. Pharmalot/Stat News.
• 9 June 2016. Por primera vez Colombia declarará un fármaco como de interés público. El Espectador.
• 9 June 2016. Minsalud fijará unilateralmente precio de medicina para la leucemia. El Tiempo.
• 29 May 2016. Cara y sello del debate por el fármaco contra la leucemia. El Tiempo.
• 28 May 2016. Kelly Slone. Op-ed: Innovation needs protection, and foreign professor’s criticism of Hatch unwarranted. The Salt Lake Tribune.
• 27 May 2016. Kyle Jaeger. The Backdoor Way the United States Pressures Other Countries to Keep Drug Prices High. Attn.
• 27 May 2016. Sanders, House Dems press USTR on Colombia license. BioCentury.
• 27 May 2016. Sens. Brown, Sanders Join Calls For Clarity On Colombia’s Licensing Of Generic Medicines. Inside U.S. Trade.
• 27 May 2016. Sergio Gómez Maseri. ‘Presión a Colombia por medicamentos sería ilegal.’ El Tiempo.
• 27 May 2016. Emily Wasserman. Sanders chastises U.S. reps over role in Gleevec CL battle. FiercePharma.
• 26 May 2016. Ed Silverman. Bernie Sanders accuses US Trade Rep of intimidating Colombia over Novartis patent. Pharmalot/Stat News.
• 26 May 2016. Para Congresistas de EE.UU., Colombia tiene derecho a modificar licencia de Novartis. W Radio.
• 26 May 2016. Zach Carter. Key Democrat Incensed Over ‘Intimidation’ For High Drug Prices. Huffington Post.
• 26 May 2016. Emily Wasserman. Tug-of-war over Novartis’ Gleevec rights in Colombia escalates with U.S. lawmakers’ challenge. FiercePharma.
• 26 May 2016. 15 House Dems Say US Pressure On Colombia Over Compulsory License Could Violate May 10 Agreement, WTO Obligations. Inside U.S. Trade.
• 26 May 2016. Adam Behsudi. Treasury proposes financial services fix, but not for TPP; HOUSE DEMS QUESTION COLOMBIA PHARMA PRESSURE. POLITICO Morning Trade.
• 25 May 2016. Ed Silverman. House Democrats blast US Trade Rep for pressuring Colombia over Novartis patent. Pharmalot/Stat News.
• 24 May 2016. Thomas Graham. Colombia appeals to World Health Organization in fight for cheaper cancer drug. Colombia Reports.
• 24 May 2016. Orrin Hatch habla a La W sobre su polémica cercanía con Novartis. W Radio.
• 23 May 2016. Carlos Delgado/Redacted Tonight. Big Pharma Holding Cancer Drug Hostage. RT.
• 21 May 2016. Justin Gardner. Leaked Memos Show U.S. Threaten Continued Violence if Colombia Challenges Big Pharma Monopoly. The Free Throught Project.
• 21 May 2016. Daniel Coronell. El Senador de Novartis. Semana.
• 21 May 2016. Luis Carlos Reyes. Op-ed: Hatch puts Colombian peace at risk to help Novartis. The Salt Lake Tribune.
• 20 May 2016. Lyra Bartell. NGOs condemn US senator for allegedly pressuring Colombia over cancer drug. Colombia Reports.
• 20 May 2016. Kejal Vyas. Colombia Threatens to Override Novartis’s Patent on Gleevec. Wall Street Journal.
• 19 May 2016. Emily Wasserman. Clock is ticking on CL deal for Novartis’ Gleevec, Colombia says. FiercePharma.
• 19 May 2016. Zach Carter. Dear Senator: Do You Really Want Cancer Drugs To Be Super-Expensive? Huffington Post.
• 19 May 2016. Alan Hernández. Colombia’s Battle With a Cancer Drug Company Could Set a Global Precedent for Generic Meds. Vice.
• 18 May 2016. Carolyn Y. Johnson and Karen DeYoung. Dispute with Swiss drugmaker has Colombian officials worried about U.S. peace funding. Washington Post.
• 18 May 2016. Mat Youkee. How Colombia’s Drugs Battle With Novartis Could Change Healthcare in Latin America: A showdown with the Swiss drugmaker is testing Colombia’s progressive new healthcare reforms. Americas Quarterly.
• 18 May 2016. Ed Silverman. Colombia to Novartis: Lower the price of your cancer drug, or else. Pharmalot/Stat News.
• 18 May 2016. Julia Symmes Cobb and Luis Jaime Acosta. Deal still possible in Colombia-Novartis cancer drug talks : minister. Reuters
• 18 May 2016. Joshua Goodman and Linda A. Johnson. Colombia battles world’s biggest drugmaker over cancer drug. In Spanish: Colombia enfrenta a mayor farmacéutica del mundo por cáncer. Associated Press.
• 17 May 2016. Ram Etwareea. Bras de fer entre la Colombie et Novartis. Le Temps.
• 17 May 2016. Eric Sagonowsky. Leaked letters show trade tensions over Colombian CL for Novartis’ Gleevec. FiercePharma.
• 17 May 2016. Christophe Koessler. Bras de fer mortel sur les génériques. Le Courrier.
• 16 May 2016. Marco Velásquez-Ruiz. ¿Es la presión ejercida por Estados Unidos sobre Colombia, en el caso Novartis, una infracción al Derecho Internacional? El Tiempo.
• 16 May 2016. Paola Ochoa. Chantaje: ¿Qué vale más: la plata de los gringos o la vida de miles de personas? El Tiempo.
• 16 May 2016. Expertos apoyan decisión de Minsalud de reducir precio del Imatinib, medicamento para el cáncer. El Espectador.
• 16 May 2016. Expertos apoyan a Minsalud en el tema Glivec. El Heraldo.
• 16 May 2016. Más de 100 expertos respaldan a Minsalud en su pulso con Novartis. W Radio.
• 16 May 2016. Ministro de Salud recibe apoyo de expertos por caso de imatinib. Radio Santa Fe.
• 16 May 2016. Expertos apoyan al MinSalud en su búsqueda para que el Imatinib sea declarado de interés público. RCN Radio.
• 15 May 2016. US Senate Warns Colombia: Don’t Lower Cost of Cancer Drug. teleSUR.
• 15 May 2016. María Mónica Monsalve, Jesús Mesa, and Sergio Silva Numa. Imatinib, un dilema de 3.200 pacientes. El Espectador.
• 15 May 2016. Expertos firman carta de apoyo a Minsalud en batalla por el imatinib. Semana.
• 14 May 2016. Zaid Jilani. Leaks Show Senate Aide Threatened Colombia Over Cheap Cancer Drug. The Intercept.
• 14 May 2016. Tom Boggioni. Revealed: Leaks show senate staffer threatened Colombia with loss of foreign aid over cheap cancer drug. Raw Story.
• 13 May 2016. Dave Johnson. Is This The Return Of US ‘Gunboat Diplomacy’ Serving Corporations? Seeing the Forest.
• 13 May 2016. Mónica Parada Llanes. “Paz Colombia no se afectará por Novartis”: María Ángela Holguín. El Heraldo.
• 13 May 2016. Novartis vs Gaviria: La batalla por la soberanía de la salud. Dinero.
• 13 May 2016. Carolina Botero Cabrera. ¿Licencia obligatoria o paz? El Espectador.
• 13 May 2016. Colombia teme EE.UU. no financie el proceso de paz por presiones de las farmacéuticas. eldiario.es.
• 13 May 2016. Glyn Moody. At The Behest Of Big Pharma, US Threatens Colombia Over Compulsory Licensing Of Swiss Drug. Techdirt.
• 13 May 2016. Sarah Karlin-Smith. Colombia fears cancer drug will spoil U.S. relations. POLITICO PRO.
• 13 May 2016. Victoria Guida. Morning Trade: Colombia’s dilemma. POLITICO.
• 13 May 2016. Adriaan Alsema. Are Swiss Novartis’ private interests threatening US peace funds for Colombia? Colombia Reports.
• 12 May 2016. Ed Silverman. Colombian health minister is warned not to sidestep Novartis patent. Pharmalot/ Stat News.
• 12 May 2016. EE.UU. aplazaría financiación del Plan Paz Colombia por pelea MinSalud-Novartis. Blu Radio.
• 12 May 2016. Por pelea con Novartis, Colombia podría perder dinero gringo para posconflicto. Pulzo.
• 12 May 2016. Plan Paz Colombia estaría en riesgo por pelea entre Gobierno y Novartis. Publimetro.co.
• 12 May 2016. Ned Pagliarulo. Colombian diplomat warns of fallout from Novartis patent battle. BioPharma Dive.
• 12 May 2016. Colombian Diplomat Suggests Drug Fight Could Spur Cuts In U.S. Aid. Inside U.S. Trade.
• 11 May 2016. Zach Carter. Colombia Fears U.S. May Reject Peace Plan To Protect Pharma Profits. Huffington Post.
• 11 May 2016. Ed Silverman. US pressures Colombia over plan to sidestep patent for a Novartis drug. Pharmalot/Stat News.
• 10 May 2016. Las presiones de EE.UU. para que Colombia no regule el precio del imatinib. El Espectador.
• 10 May 2016. Andrew Goldman. Senator Hatch, before pressuring Colombia over cancer drug compulsory license, wanted one for Napster. KEI.
• 9 May 2016. EE.UU. amenaza con torpedear ayuda económica para posconflicto. Noticias Uno.